Proteome Sciences (LON:PRM) Trading Up 22.7% – Still a Buy?

Proteome Sciences plc (LON:PRM)’s share price was up 22.7% during trading on Wednesday . The stock traded as high as GBX 2 and last traded at GBX 2. Approximately 308,437 shares traded hands during trading, a decline of 25% from the average daily volume of 410,584 shares. The stock had previously closed at GBX 1.63.

Proteome Sciences Trading Down 13.5%

The company has a current ratio of 0.13, a quick ratio of 0.37 and a debt-to-equity ratio of -165.46. The firm has a 50-day moving average of GBX 1.61 and a 200 day moving average of GBX 1.97. The company has a market cap of £4.95 million, a P/E ratio of -1.36 and a beta of 0.07.

Proteome Sciences (LON:PRM) last announced its earnings results on Wednesday, April 15th. The company reported GBX (1.04) EPS for the quarter. Proteome Sciences had a negative net margin of 81.50% and a positive return on equity of 33.80%. The business had revenue of GBX 376 million for the quarter.

Proteome Sciences Company Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.